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Abstract
Background: Huntington’s disease (HD) is a polyglutamine-expanded related neurodegenerative disease. Despite the
ubiquitous expression of expanded, polyQ-Huntingtin (ExpHtt) in the brain, striatal neurons present a higher susceptibility
to the mutation. A commonly admitted hypothesis is that Dopaminergic inputs participate to this vulnerability. We
previously showed that D2 receptor stimulation increased aggregate formation and neuronal death induced by ExpHtt in
primary striatal neurons in culture, and chronic D2 antagonist treatment protects striatal dysfunctions induced by ExpHtt in
a lentiviral-induced model system in vivo. The present work was designed to elucidate the signalling pathways involved,
downstream D2 receptor (D2R) stimulation, in striatal vulnerability to ExpHtt.
Methodology/Principal Findings: Using primary striatal neurons in culture, transfected with a tagged-GFP version of
human exon 1 ExpHtt, and siRNAs against D2R or D1R, we confirm that DA potentiates neuronal dysfunctions via D2R but
not D1R stimulation. We demonstrate that D2 agonist treatment induces neuritic retraction and growth cone collapse in
Htt- and ExpHtt expressing neurons. We then tested a possible involvement of the Rho/ROCK signalling pathway, which
plays a key role in the dynamic of the cytoskeleton, in these processes. The pharmacological inhibitors of ROCK (Y27632 and
Hydroxyfasudil), as well as siRNAs against ROCK-II, reversed D2-related effects on neuritic retraction and growth cone
collapse. We show a coupling between D2 receptor stimulation and Rho activation, as well as hyperphosphorylation of
Cofilin, a downstream effector of ROCK-II pathway. Importantly, D2 agonist-mediated potentiation of aggregate formation
and neuronal death induced by ExpHtt, was totally reversed by Y27632 and Hydroxyfasudil and ROCK-II siRNAs.
Conclusions/Significance: Our data provide the first demonstration that D2R-induced vulnerability in HD is critically linked
to the activation of the Rho/ROCK signalling pathway. The inclusion of Rho/ROCK inhibitors could be an interesting
therapeutic option aimed at forestalling the onset of the disease.
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Introduction
Huntington’s disease (HD), a neurodegenerative disorder char-
acterized by motor, cognitive, and psychiatric disorders (1) is caused
by abnormal expansion of a CAG tract in exon 1 of the IT15 gene.
Thismutation leads to an abnormal polyglutamine expansion in the
N-terminal part of the huntingtin (Htt) protein. Cleavage of polyQ
expanded huntingtin (ExpHtt) by caspases, leads to the release of N-
terminalfragmentscontainingthepolyglutamine repeats,which can
aggregate in neurites, cytoplasm, and nuclei.
Despite ubiquitous expression of Htt throughout the brain and
other tissues, medium spiny GABAergic neurons in the striatum
predominantly degenerate in the brain of HD patients [1]. Among
various mechanisms [2] dopamine (DA) may be important in this
preferential vulnerability. HD neuropathology progresses in the
striatum according to the same dorsoventral gradient as local DA
concentration [1,3,4]. Variations of DA concentration can
modulate striatal death in various models [5,6,7]. Dopamine
transporter knock-out (DAT-/-) mice display both spontaneous
striatal death and behavioral alterations that resemble HD [8].
When mated to knock-in HD mice these mice showed exacerbation
ofHDpathophysiologyand accelerationofaggregateformation[9].
We recently extended these observations and demonstrated, in vitro,
that DA accelerates two neuropathological hallmarks induced by
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8287expHtt: aggregate formation and striatal neuron death [10]. On this
in vitro model system, DA exerted a dual role on striatal death, via
two independent pathways. One was due to reactive oxygen species
and activation of the pro-apoptotic cJun-N terminal Kinase (JNK)
pathway, the other one was specifically linked to D2 receptor
stimulation and aggregate formation. Importantly, D2 antagonist
treatments in vitro and in vivo protected from aggregate formation
and striatal dysfunctions induced by ExpHtt [10,11].
Aggregate formation is known to be involved in the destabiliza-
tion of microtubules and disorganization of the dendritic arbors,
which are early events in the pathogenic mechanisms involved in
HD [12,13,14,15,16]. One critical intracellular signalling pathway
involved in actin cytoskeleton rearrangements and neurites
elongation is the Rho/ROCK pathway [17,18,19]. This pathway
has recently been shown to be involved in aggregate formation and
cell death induced by ExpHtt, in drosophila or cell line models
[20,21,22]. In the present study, we show a coupling of D2 receptor
to this signalling pathway. The inhibition of ROCK activity using
selective inhibitors, of knock-down of ROCK-IIexpression reversed
D2 agonist-mediated aggregate formation, neuritic retraction and
neuronal death induced by ExpHtt. By contrast, these treatments
failed to affect neuronal dysfunctions induced by ExpHtt itself. We
thus conclude that striatal neurons vulnerability in HD may be at
least in part, mediated by the Rho/ROCK signalling pathway. The
inclusion of Rho/ROCK inhibitors could be an interesting
therapeutic option aimed at forestalling the onset of the disease.
Results
DA-Mediated Potentiation of Aggregates Formation and
Neuronal Death Induced by ExpHtt in Striatal Neurons
Involved D2R but Not D1R Stimulation
Using primary cultures of striatal neurons expressing exon 1 of
Huntingtin with a polyglutamine stretch (103Q: ExpHtt) fused to
EGFP, we recently showed that DA, via D2 receptor stimulation,
potentiates aggregate formation and neurodegenerescence in-
duced by ExpHtt. These results were based on pharmacological
studies made on primary striatal neurons from WT or knock-out
mice for D2 receptors (D2R) [10]. Other in vitro studies
documented that D1 receptors (D1R) play a role in mutant
huntingtin-mediated aggregates formation and apoptosis
[23,24,25]. In order to clarify the specific contribution of D1R
and D2R on DA-mediated potentiation of aggregates formation
and neuronal death in our model system, we used molecular tools
to abrogate D1R and D2R expression. We first showed expression
of both D1R and D2R in primary cultures from E14 striatal
neurons after 7 days in vitro (DIV 7) (Fig. 1A–D). Of interest, both
the full-length and spliced version of D2 receptors (D2L and D2S)
were present in these striatal neurons (Fig. 1B). Specific
invalidation of D1R and D2R mRNA and protein expression
was achieved following siRNA transfection in striatal neurons
(Fig. 1). Then, using this siRNA molecular approach, we focused
on the role of both D1and D2 receptors in DA-mediated
potentiation of aggregates formation and neuronal death induced
by ExpHtt. We took advantages of GFP-tagged cDNAsto visualize
expression and localization of Htt and ExpHtt in transfected
neurons (Fig. 2A). As a consequence, aggregates of ExpHtt was
visualized owing to GFP labelling. Knockdown of D2R (both D2L
and D2S) but not D1R, using specific siRNAs resulted in a total
inhibition of DA-induced aggregates formation (Fig. 2B), as
previously demonstrated from D2R-knock out mice [10]. As
expected, D2R siRNA only partially inhibited DA-mediated
neuronal death in ExpHtt expressing neurons (Fig. 2C). Further-
more, specific knockdown of D1R did not affect neuronal death in
ExpHtt expressing neurons (Fig. 2C). Thus, having shown the
specific involvement of D2R but not D1R stimulation in aggregate
formation and neuronal death, we used for the following
experiments a specific D2R agonist, quinpirole (Quin), to study
Figure1.ValidationofD1RandD2R specificsiRNAinprimarystriatalneurons. A–D: primary striatalneuronsweretransfectedornot (Control)
with Cont siRNA, D1R siRNA and D2R siRNA. After 72 hours, mRNAs were extracted followed by RT-PCR (A andB) andprotein expression levels detected
byimmunoblot(CandD). A:RT-PCRofD1Rgene and,B:RT-PCRD2R.Note the presenceofbothD2Rlongandshort isoforms.ForAandB:ARPgenewas
used as anhousekeeping gene.B andD: immunoblot using specificanti-D1R (C), andspecific D2R (D) antibodies. b-tubulin was used for control loading.
doi:10.1371/journal.pone.0008287.g001
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induced cellular dysfunctions.
D2 Receptor Stimulation Potentiates Neuritic Retraction
and Growth Cone Collapse Induced by ExpHtt in Striatal
Neurons
Once aggregates of ExpHtt are formed, they destabilize
microtubules and disrupt the cellular architecture [15]. We first
investigated whether ExpHtt had any effect on the dynamic
organization of the cytoskeleton and neuritic outgrowth in our
model system. Using MAP2 (Microtubule-Associated-protein)
immunostaining we analyzed the mean neuritic length of
transfected neurons (Fig. 3A, C). Statistical analyses revealed a
significant decrease of neuritic length (225%) in ExpHtt
expressing neurons when compared to Htt-transfected cells. We
then analyzed a possible potentiation of DA and/or D2-Receptor
stimulation on ExpHtt-mediated neuritic retraction. All experi-
ments were performed in the presence of anti-oxidants, in order to
avoid indirect effect of DA auto-oxidation. DA and quinpirole
treatments potentiated significantly the reduction of neuritic length
induced by ExpHtt alone (Fig. 3A, C). Importantly, DA and
quinpirole treatments also induced a significant decrease of
neuritic length in non-transfected striatal neurons (230%; data
not shown) as well as in Htt-expressing neurons (Fig. 3A, C). In
both Htt- and ExpHtt-expressing neurons, DA effects on neuritic
retraction were reversed by the selective D2 receptor antagonist,
raclopride (Fig. 3C). This indicates that the major effects exerted
by DA on neuritic retraction are mediated by D2 receptor
stimulation.
Neuritic retraction is accompanied by a disorganization of actin
filaments that can be visualized by rhodamine-phalloidin labelling.
The filaments of actin are concentrated in filopodes and
lamellipodes of growth cones (Fig. 3B). Actin filaments are mainly
observed at the tips of the neurites and present very well structured
and large growth cones, in most neurons expressing Htt. About
20% of collapse was found in Htt-expressing neurons (Fig. 3B, D).
A significant increase of growth cone collapse was observed in
ExpHtt-expressing neurons (42% of collapse) (Fig. 3B, D). This
collapse was even higher upon quinpirole treatment, in both Htt
and ExpHtt transfected neurons (30% and 65%, respectively,
Fig. 3D), indicating that D2 receptor stimulation promotes a
disorganization of actin filaments.
D2-R Mediated Neuritic Retraction and Growth Cone
Collapse Is Associated with ROCK-II Activation in Striatal
Neurons
Various signalling pathways participate in the dynamic
reorganization of the cytoskeleton and neuritic elongation, among
which the Rho/ROCK signalling pathway is thought to play a key
role [17,18,19]. We thus investigated a possible involvement of this
pathway in neuritic retraction induced by ExpHtt in the presence
or not of the D2 agonist treatment. The ROCK pharmacological
inhibitors Y27632 and Hydroxyfasudil were used as a first
approach. These inhibitors, applied 30 minutes prior to, and
during quinpirole treatment, reversed D2-mediated effects on
neuritic retraction in Htt- and ExpHtt- expressing neurons
(Fig. 4A). By contrast, they failed to affect neuritic retraction
induced by ExpHtt alone (Fig. 4A). We then wished to confirm
these observations using siRNAs to abolish ROCK protein
expression. Two different genes encode ROCK, giving rise to
ROCK-I and ROCK-II. Both proteins are implicated in the
formation of stress fibers and suppression of neurite outgrowth and
are ubiquitiously expressed, with an enrichment of ROCK-II in
Figure 2. DA-mediated potentiation of aggregates formation
and neuronal death induced by ExpHtt in striatal neurons
involves D2R but not D1R stimulation. A: Immunocytochemical
detection ofHttwas performedonstriatal neurons transfectedwitheither
GFP alone, GFP-tagged Htt or GFP-tagged ExpHtt. Nuclei were labelled
using Hoechst (blue). Note that ExpHtt and GFP perfectly colocalize in
aggregates. B and C:Seventy two hours after RNA interference procedure,
primary neurons were transfected with Htt or ExpHtt and treated with DA
(100 mM)for10(B)or24(C)hours.B:quantificationoftransfectedneurons
with aggregates of ExpHtt. C: quantification of surviving transfected
neurons based on Hoechst labeling. Data were analyzed from at least 3
independent experiments (100transfected neurons per conditionandper
experiment) and expressed as mean6SEM. (***P,0.001, **P,0.005,
*P,0.05, ns: non significant).
doi:10.1371/journal.pone.0008287.g002
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PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8287Figure 3. D2 receptor stimulation potentiates neuritic retraction and growth cone collapse induced by ExpHtt in striatal neurons. A)
Immunohistochemical detection of MAP2 protein (red) was performed on striatal neurons transfected with either Htt or ExpHtt (GFP) and treated or
not for 14 hours with quinpirole (10 mM). Nuclei were labelled using Hoechst (blue). The white arrow in the merge panel points to a neurite in
transfected neurons. B) Phalloidin labelling of F-actin was assayed to visualize growth cone on Htt and ExpHtt-expressing striatal neurons. White
arrows and insert in the merge panel depict a growth cone in a transfected neuron. C) Quantification of mean neuritic length in transfected neurons
was determined from MAP2 staining using ImageJ software in Htt (white bars) and ExpHtt (black bars)-expressing neurons, treated or not with
dopamine (DA, 100 mM), quinpirole (Quin, 10 mM) or DA plus raclopride (1 mM) for 14 hours. D) Quantification of growth cone collapse was
determined on phalloidin staining in Htt (white bars) and ExpHtt (black bars)- transfected neurons treated or not with quinpirole (10 mM) for
14 hours. C and D) Data were analyzed from at least 3 independent experiments (100 transfected neurons per condition and per experiment) and
expressed as mean6SEM.(***P,0.001, ns: non significant).
doi:10.1371/journal.pone.0008287.g003
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PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8287Figure 4. D2-R mediated neuritic retraction and growth cone collapse is associated with ROCK-II activation in striatal neurons. A)
Quantification of mean neuritic length in neurons transfected with Htt (white bars) or ExpHtt (black bars) was determined from MAP-2 staining.
Transfected neurons were pre-treated with ROCK pharmacological inhibitors Y27632 (10 mM) or Hydroxyfasudil (10 mM) 30 minutes prior to and
during quinpirole treatment (10 mM) (14 hours). Data are expressed as mean6SEM from 3 independent experiments (100 transfected neurons per
condition and per experiment) (***P,0.001). B) Striatal extracts from adult mouse (striatal extracts), striatal neurons in culture (striatal cultures) and
HEK293 cells extracts (HEK cells) were processed for Western-blot with specific antibodies against ROCK-I (left) and ROCK-II (right). Similar amounts of
proteins were loaded in each case. b-tubulin was used for control loading. Note the high expression level of ROCK-II in both striatal extracts and
culture when compared to ROCK-I expression. C) Control siRNA (50 nM) or siRNA targeting ROCK-II (50 nM) were transfected in primary striatal
neurons for 72 hours. Extracts from siRNA-transfected or non transfected (control) neurons were processed for Western-blot with specific antibodies
against ROCK-II and b-tubulin. Note the knock-down of ROCK-II expression. D) Quantification of mean neuritic length in neurons transfected with Htt
(white bars) or ExpHtt (black bars) after quinpirole treatment (10 mM) alone or in the presence of control siRNA (50 nM) or ROCK-II siRNA (50 nM).
Data are expressed as mean6SEM from 3 independent experiments (100 transfected neurons per condition and per experiment). (***P,0.005,
**P,0.05). E) Quantification of growth cone collapse in neurons transfected with Htt (white bars) or ExpHtt (black bars) after quinpirole treatment
(10 mM) for 14 hours alone or in the presence of ROCK inhibitors (10 mM) or ROCK-II siRNA (50 nM). Data are expressed as mean6SEM from 3
independent experiments (100 transfected neurons per condition and per experiment). In these experiments, neurons transfected with control siRNA
showed no significant difference with non transfected neurons (control) alone (***P,0.001).
doi:10.1371/journal.pone.0008287.g004
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ROCK-II expression in striata from adult mice (Fig. 4B: striatal
extracts), in striatal neurons in culture (Fig. 4B striatal culture), and
in HEK cells extracts as a positive control by western blot. Both
proteins were found at 160 KDa, their expected molecular weight,
in HEK cells (Fig. 4B). Very low levels of ROCK-I were found
when compared to ROCK-II in striatal cells both in vivo and in vitro
(Fig. 4B).
Further studies were thus focused on ROCK-II knock-down.
Having established the efficiency of siRNAs on ROCK-II
expression by western-blot (Fig. 4C), we transfected them (DIV
4) along with cDNAs encoding Htt or ExpHtt (DIV7). The
ROCK-II knock-down effects were analyzed on neuritic retraction
14 hours later, in the presence of quinpirole (Fig. 4D). ROCK-II
knock-down totally reversed potentiation by quinpirole of ExpHtt-
induced neuritic retraction. Similar results were found using
specific inhibitors of ROCK, Y27632 and Hydroxyfasudil. By
contrast, neither molecular nor pharmacological inhibition of
Rho/ROCK signalling reversed neuritic retraction induced by
ExpHtt alone. A total reversal of D2-mediating effects was also
found on growth cone collapse, without modification of ExpHtt-
induced effects (Fig. 4E).
Altogether our data provide a strong, albeit indirect, evidence of
a coupling between D2 receptors and Rho/ROCK activation.
The DA/D2 receptor subtype has been classically coupled to
inhibition of adenylate cyclase [26], but recent evidence in the
literature also supported a coupling between D2 receptors and
Rho-GTP binding protein [27]. We thus wished to provide a
direct evidence of Rho/ROCK activation by D2 receptor
stimulation instriatal neurons. Rho activity was measured using
the ratio of Rho-GTP levels by comparison to total Rho proteins
(Fig. 5A,B). Both DA and quinpirole treatments significantly
increased Rho activity after 15 min of treatment. Once activated
by Rho, ROCK proteins can phosphorylate several substrates,
including LIM kinase which phosphorylates Cofilin at Ser3 [28].
Cofilin critically controls actin filament dynamics and reorganiza-
tion. Using immunocytochemical approaches, we investigated
phosphorylation of cofilin after quinpirole treatments on striatal
neurons and found an hyperphosphorylation after 20 minutes of
treatment in about 35% of striatal neurons (Fig. 5C–E). This
hyperphosphorylation was reversed by ROCK inhibitors (Fig. 5D)
and ROCK-II siRNA treatments (Fig. 5E). Altogether these data
provide the first evidence that D2 receptor stimulation induces
phosphorylation of cofilin via the Rho/ROCK signalling pathway
in striatal neurons.
D2-R Stimulation Potentiates ExpHtt-Induced Aggregate
Formation via ROCK-II Activation
The pattern of ExpHtt expression into striatal neurons can be
observed owing to the GFP tag at the C-terminal region of exon 1
ExpHtt. Thus, ten hours after transfection, ExpHtt shows a diffuse
pattern in 65% of transfected neurons (Fig. 6A, upper panel), while
aggregates of ExpHtt are observed in the remaining transfected
neurons (35%) (Fig. 6A, lower panel). According to our previous
observations [10], D2 agonist (quinpirole) treatment significantly
increased the number of transfected neurons containing aggregates
of ExpHtt (52% versus 35%) (Fig. 6B).
To gain insights into the mechanisms that lead to D2 effects on
aggregate formation, we investigated the role of ROCK inhibitors
and ROCK siRNAs. D2-mediated aggregate formation was totally
reversed by ROCK inhibitors, without any significant effects on
aggregates formed by ExpHtt alone. These data were confirmed
using ROCK-II siRNAs (Fig. 6B). Thus, our findings indicate that
ROCK-II signalling is implicated, downstream D2 receptors, in
the potentiation of ExpHtt aggregate formation.
D2-R Stimulation Potentiates ExpHtt-Induced Neuronal
Death via ROCK-II Activation
We previously showed [10] that D2 agonist treatment
potentiated striatal death induced by ExpHtt. Cell survival was
analyzed 24 hours after transfection by appreciation of nucleus
morphology (DNA fragmentation) by Hoechst staining (Fig. 7A).
Quinpirole significantly potentiated ExpHtt-induced neuronal
death without affecting cell survival in Htt-expressing neurons.
The ROCK inhibitors (Y-27632 or Hydroxyfasudil) and ROCK-
II siRNA totally rescued toxicity induced by the D2 agonist in
ExpHtt-expressing striatal neurons with no effects against toxicity
induced by ExpHtt itself (Fig. 7B). Altogether, these data indicate
that the Rho/ROCK-II signalling pathway is a major pathway
downstream D2 receptor for mediating toxicity in ExpHtt-
expressing neurons.
Discussion
In the present work, we wished to analyze how DA via DA
receptors stimulation might account for aggregate formation and
potentiation of neuronal death in ExpHtt expressing striatal
neurons. We first confirm our previous results [10,11] showing
that DA potentiation of ExpHtt toxicity is mediated via D2R but
not D1R stimulation, in our model system, i.e. in striatal neurons
expressing a truncated version of ExpHtt. We show the first
evidence for a coupling of D2 receptors to the Rho/ROCK-II
signalling pathway. In cultured striatal neurons, inhibition of this
pathway reversed DA/D2 receptor-mediated neuritic retraction,
growth cone collapse, aggregate formation and neuronal death
induced by ExpHtt in the presence of D2 agonist. By contrast with
findings in other model systems of HD (Drosophila, and HEK
cells), we failed to demonstrate a clear involvement of ROCK in
ExpHtt induced cellular phenotypes in striatal neurons.
Neurodegeneration in HD occurs most prominently in the basal
ganglia and neocortex. Striatal neurons show a range of
vulnerabilities in Huntington’s disease. Medium Spiny Neurons
(MSNs) are the first affected striatal cells while interneurons are
spared, even at a late stage of the disease. Among the MSNs, the
GABAergic/enkephalinergic, which preferentially express D2
receptors and project to the external segment of globus pallidus
(Gpe) tend to degenenerate before the substance P/dynorphiner-
gic striato-nigral neurons expressing D1 receptors [29,30,31]. In
HD patients, primates and mouse models of HD, aggregates
appear first in the neuropil [9,14,16,32,33,34], where they are
thought to be toxic by poisoning the axonal transport [11,16,35].
The reduction of these aggregates leads to an improvement of the
phenotype in HD mice [36]. Interestingly, the Substancia Nigra
(SN) and the GPe, which receive afferents from the D2R-
expressing striatal neurons, are the first brain areas where neuropil
aggregates appear, in mice and human [16,34,37,38]. Hyperdo-
paminergic HD mice display an accelerated clinical and
neuropathological phenotype with early formation of neuropil
aggregates that predominate in the GPe [9], which express D2R
but not D1R. In primary culture of striatal neurons expressing
ExpHtt, D2 receptor stimulation increases the formation of
neuropil aggregates, while striatal neurons from D2R knock-out
mice fail to show any vulnerability to DA for aggregate formation
(11). By contrast, D1R stimulation did not influence the total
number of mutant Htt aggregates in SK-N-MC expressing ExpHtt
(N-term-103Q) [24]. These observations were strengthened in the
present work, where D2R- but not D1R- siRNAs prevented DA-
Dopamine/D2 Receptor and HD
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findings suggest that D2 receptor stimulation plays a key role in
GABAergic/MSN vulnerability to ExpHtt, via potentiation of
neuropil aggregates and axonal poisoning. Other deleterious
effects of D2 receptor stimulation on ExpHtt induced neuronal
dysfunctions were recently unraveled (41). In an elegant study, the
authors showed that D2 receptor stimulation increased ExpHtt-
induced deficiency of mitochondrial complex II protein activity,
which plays a key role in oxidative energy metabolism. In cellular
models expressing the full length mutant Htt, immortalized
mutant STHdh
Q111, striatal neuronal progenitor cell lines or
striatal neurons from YAC128 mice, D1R stimulation but not
D2R is involved in DA-mediated cell death and potentiation of
glutamate toxicity [23,25]. In these studies, D1R-mediated effects
were critically linked to increased calcium influx. Thus, depending
on the expression of the full length or the cleaved fragment of
Figure 5. DA and quinpirole activate Rho/ROCK pathway on striatal neurons. A) Western-blot detection of Rho-GTP (top) along with Total
Rho (middle) and b-tubulin (bottom) after 15 minutes of treatment with DA (100 mM) and quinpirole (10 mM) in non-transfected striatal neurons. B)
Quantification of Rho-GTP activity from 3 independent experiments. Total Rho was expressed as Arbitrary Unit (AU). Note the significant increase of
Rho-GTP/Total Rho after 15 minutes of DA (Grey bar) and quinpirole (Black bars) treatment (*P,0.05). C) Immunocytochemical detection of P-Cofilin
(green) and MAP2 (red) proteins 20 minutes after quinpirole treatment (10 mM, lower panel) and in Control conditions (upper panel). Nuclei were
labelled using Hoechst (blue). D and E) Quantification of P-Cofilin positive neurons (n=3 independent experiments, 100 neurons per experiment)
using Metamorph software after quinpirole treatment alone or in the presence (D) of pharmacological inhibitors of ROCK, Hydroxyfasudil (10 mM) and
Y-27632 (10 mM) or (E) after transfection of siRNA ROCK-II. B, D and E, Data are expressed as mean6SEM (***P,0.001, **P,0.005, *P,0.05).
doi:10.1371/journal.pone.0008287.g005
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in DA-mediated toxicity on striatal neurons.
In our in vitro model system, D2 receptor stimulation increased
neuritic retraction and growth cone collapse in mutant- but also
normal Htt-expressing neurons. This observation corroborates in
vivo data showing that D2 receptors stimulation results in pruning
of the terminal arbor of substantia nigra pars compacta (SNpc) DA
neurons [39,40]. Furthermore, the genetic invalidation of D2
receptor in mice resulted in a significant increase in terminal tree
size of these neurons, as well as the density of varicosities in the
caudate-putamen (42,43). We can thus hypothesise that the
disorganization of the neuritic arbors described in HD might be,
at least in part, due to local D2 receptor stimulation. D2 receptors
are classically described as negative regulators of the cAMP/PKA
pathway, via coupling to Gai/o [41]. They can also couple to
phospholipase (PLCb) via Gq, mobilize intracellular calcium stores
[42] and activate the MAPK/ERK signalling cascade [42,43].
Dopaminergic stimulation of D2 receptors can also activate or
inhibit the Akt phosphorylation level (Thr308), depending on the
time of stimulation, short or long, respectively [43,44]. In the
present study, we present the first evidence for a coupling between
D2 receptors and the Rho/ROCK signalling pathway. Such
coupling was suggested previously, by a study showing that D2-
mediated activation of Phospholipase D (PLD) was abolished by
preincubation of the cells with C3 exoenzyme, a specific inhibitor
of the Rho proteins [27]. Other G protein-coupled receptors have
been described for their ability to activate Rho proteins. The
classical activator of this pathway is the lysophosphatidic acid
(LPA) receptor which acts through G12/G13 to activate RhoA
and ROCK and lead to neuritic retraction and growth cone
collapse [45,46,47] The details of the mechanism by which D2
receptor stimulates Rho proteins remain unclear but could involve
the scaffolding proteins b-arrestin that have been associated with
the activation of Rho downstream Angiotensin A2 receptors [48]
and are known to be critical for D2 receptor internalization [49].
ROCK proteins are principal mediators of RhoA activity in the
nervous system where they have been largely reported as
regulators of neuritic length and growth cone collapse [50].
Screening for biologically active molecules that inhibit polygluta-
mine aggregation, lead to the identification of a pharmacological
ROCK inhibitor, Y-27632 [21,22] When Y-27632 was adminis-
trated in a Drosophila model of HD, it reduced Htt-exon1 (93Q)
induced neurodegeneration. In HEK cell line expressing Htt
exon1 (72Q), it was necessary to knock-down both ROCK-I and
Protein Kinase C-related protein (PRK2) proteins to abolish
polyglutamine aggregation [21] In Neuro2a cells expressing Htt-
exon1 (150Q), knock-down of ROCK-II and ROCK-I reduced
aggregation [51]. In striatal neurons, in vitro and in vivo, we found a
poor expression of ROCK-I, while ROCK-II was strongly
expressed. Global inhibitors of ROCK or knock-down of
ROCK-II expression, failed to reverse neuronal dysfunctions
induced by ExpHtt by itself. However, the pharmacological
inhibitor of ROCK, as well as ROCK-II-siRNAs, reversed D2-
mediated effects on ExpHtt-induced phenotype. We thus propose
that, in striatal neurons, the Rho/ROCK-II signalling pathway is
critically involved in D2-mediated vulnerability in HD. Interest-
ingly, ROCK proteins have been proposed as a promising
therapeutic target in various neurological conditions [52]. In the
CNS, inhibition of ROCK using Y27632 promotes axon growth
after spinal cord injury in experimental animal models [53] and
reduces the expression of amyloid-bpeptide in a mouse model of
Alzheimer’s disease [54].
Because long term pharmacological blockade of D2 receptors
may be poorly tolerated in patients [55,56], the inclusion of
Rho/ROCK inhibitors could be an interesting therapeutic
option to target the vulnerability of D2-R expressing striatal
neurons in HD.
Materials and Methods
Mouse Husbandry
Mice were housed in a temperature-controlled room main-
tained on a light/dark cycle. Food and water were available ad
libitum. Experiments were performed in accordance with standard
ethical guidelines (U.S. National Institutes of Health publication nu
85-23, revised 1985, and the European Committee Guidelines on
the Care and Use of Laboratory Animals directive 86/609/EEC).
Figure 6. D2-R increases ExpHtt aggregates formation via
ROCK-II activation in striatal neurons. A) ExpHtt aggregates
detection based on GFP fluorescence in primary striatal neurons
transfected with ExpHtt (tagged with GFP) for 10 hours and MAP2
immunostaining (red). Note, at this time point, that ExpHtt present
either a diffuse expression pattern (top panel) as well as aggregates
formation (bottom panel). B) Quantification of ExpHtt-transfected
neurons with aggregates after quinpirole treatment (10 mM) for
10 hours alone or in the presence of pharmacological inhibition of
ROCK (Y27632, 10 mM and Hydroxyfasudil, 10 mM) or ROCK-II siRNA
(50 nM). Data are expressed as mean6SEM from 3 independent
experiments (100 transfected neurons per condition and per experi-
ment) (***P,0.001, ns: non significant).
doi:10.1371/journal.pone.0008287.g006
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Primary striatal neurons were dissected out from 14 days old
embryos from pregnant Swiss mice (Janvier, Le Genest Saint Isle,
France) as previously described [43]. After dissociation, cell pellets
were resuspended in Neurobasal medium supplemented with B27
(Invitrogen), 500 nM L-glutamine, 60 mg/ml Pennicilin-strepto-
mycin and 25 mM b-mercapto-ethanol and then plated on poly-L-
lysine-coated 24-well (1,33610
5 cells by well) or 6-well plates
(6,321610
5 cells by well) at 37uC in a humidified 5% CO2
incubator. Using this preparation, the cell culture contains in
majority cells from neuronal and not glial origin.
After 7 days in culture, neurons grown in 24 well plates, were
transiently transfected with GFP-tagged Htt constructs (provided
by HDF Resource Bank, UCLA) encoding the first exon of human
Htt containing either 25 (Htt) or 103 (ExpHtt) continuous CAA or
CAG repeats. The sequence encoding an enhanced Green
Fluorescence Protein (GFP) was inserted in frame at the C-
terminus of each construct. Three hours and half after
transfection, the medium was removed and replaced by the
complete Neurobasal Medium containing dopamine (DA,
100 mM, Calbiochem), quinpirole (Quin, 10 mM RBI). Cells were
then replaced at 37uC for the appropriate time. For the
pharmacological treatments, Y-27632, (10 mM; Tocris) Hydro-
xyfasudil (10 mM; Sigma) or Raclopride (Raclo, 1 mM Sigma) were
added 30 min before and during quinpirole treatment.
RNA Interference
SiRNAs targeted dopamine D1 (D1R), both isoforms of
dopamine D2 (D2R) receptors, D2Long and D2Short (D2LR
and D2SR, respectively) and ROCK-II were designed to
specifically interfere with dopamine D1R, D2R and ROCK-II
expression. The target sequences were as follows: D1R, 59-
CCUGGAAGAUGCCGAGGAU-39; D2R, 59-CCAGAGAG-
GACCCGGUAUA-39 and ROCK-II, 59-CAAUGAAGCUU-
CUUAGUAA-39 (Eurogentec). Neurons were transfected at day
in vitro 4 (DIV) with 50 nM of siRNA against D1R, D2R and
ROCK-II or siRNA control (Cont siRNA #2, Ambion). After
72 hours of silencing, primary neurons were used for transfections
experiments and drug treatment.
RNA Isolation and RT-PCR
Seventy two hours after transfection with D1R or D2R siRNAs,
total mRNA was isolated using RNeasy mini kit (Qiagen) following
the manufacturer’s instructions. Reverse transcription was per-
Figure 7. D2-R potentiates striatal neuronal death induced by ExpHtt via ROCK-II activation. A) Immunohistochemical detection of MAP2
protein (red) and nuclei labelling using Hoechst (blue) were performed on striatal neurons transfected for 24 hours with either Htt (top panel) or
ExpHtt (bottom panel). The white arrow in the Hoechst panel points to a healthy nucleus (top panel) a fragmented nucleus (bottom planel) in an Htt-
and ExpHtt-transfected neuron, respectively. B) Quantification of surviving transfected neurons based on Hoechst labelling. Neurons transfected with
Htt (white bars) or ExpHtt (black bars) were treated with quinpirole (10 mM) for 24 hours alone or in the presence of pharmacological inhibition of
ROCK (Y27632, 10 mM and Hydroxyfasudil, 10 mM) or ROCK-II siRNA (50 nM). Data are expressed as mean6SEM from 3 independent experiments (100
transfected neurons per condition and per experiment)(***P,0.001, *P,0.05, ns: non significant).
doi:10.1371/journal.pone.0008287.g007
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amplificationwithspecificprimers(EurogentecS.A.).Thenucleotide
sequences of the primers were as follows: D1R, forward 59-
TTCTTCCTGGTATGGCTTGG-39,r e v e r s e5 9-GCTTAGC-
CCTCACGTTCTTG-39; D2LR, forward 59-AACTGTACC-
CACCCTGAGGA-39,r e v e r s e5 9-GTTGCTATGTAGACCGTG
-39 and D2SR, forward 59-CACCACTCAAGGATGCTGCCCG-
39, reverse 59-GTTGCTATGTAGACCGTG -39. Amplification of
Arginin Rich Protein (ARP), used as an housekeeping gene, was
performed using the following primers forward 59-
GAACGTCGTCTTCGTGTTCA-39,r e v e r s e5 9- AAAACCTG-
GACGAAGGAGGT -39.
Immunocytochemistry and Histological Analysis
Striatal neurons were fixed in 2% paraformaldehyde in PBS for
40 minutes at room temperature and permeabilized with
Methanol/Acetone (1:1 ratio) for 10 min at 4uC. After washing
with PBS, cells were preincubated with blocking buffer (10%
Normal Goat Serum in PBS) at room temperature for 1 h and
then incubated with primary antibody in PBS overnight at 4uC:
mouse anti-microtubule-associated protein 2 (1/1000, Sigma),
rabbit anti-P-Cofilin (1/500, Cell Signaling,) and mouse anti-
Huntingtin (1/1000, Chemicon). Cells were rinsed with PBS and
incubated for 2 h at room temperature with the secondary
antibody, Cy3-conjugated anti-mouse IgG (1/2000,Jackson Lab-
oratories) or Rabbit-FITC (1/200, Sigma). To analyze the nuclei
morphology, cells were stained with Hoechst (1/20000 in PBS) for
5 min at room temperature, followed by three PBS washes.
Aggregates of ExpHtt were visualized by GFP staining. The cells
were mounted under cover slips using a Vectashield medium
(Vector Laboratories) and examined with a Leica DM4000B
fluorescence microscope (X40). The percentage of transfected
neurons containing aggregates of Exp-Htt were determined by
counting neurons containing aggregated GFP versus diffuse GFP.
Neurons containing condensed or fragmented nuclei were scored
as dying cells. The neuritic length was evaluated by tracing the
neurites using the software ImageJ (version 1.34 s). The actin
cytoskeleton staining was performed by incubating fixed cells with
phalloı ¨dine TRITC (1/500) diluted in PBS-2% BSA for 20 min at
room temperature. Each experiment was conducted in triplicate,
and at least 100 transfected neurons were randomly analyzed in
each experiment.
Cell Extracts and Western Blot Analysis
Samples were prepared from neurons and HEK293 cells
homogenized in a boiling lysis buffer containing 1% SDS and
1 mM sodium orthovanadate and briefly sonicated. Equal
amounts of proteins were resolved by SDS-PAGE gels and
transfered to PVDF membrane (Amersham). After blocking in 5%
nonfat dry milk (for ROCK-I and ROCK-II) or 5% BSA (Bovine
Serum Albumin, SIGMA) (for D1R and D2R immunobloting) in
TBS for 1 h at room temperature, membranes were incubated
overnight at 4uC with primary antibodies, rabbit polyclonal anti-
ROCK-I anti-ROCK-II (1/500, Santa Cruz), mouse monoclonal
anti-D1R (1/250, Millipore), rabbit polyclonal anti-D2R (1/1000,
Millipore) and mouse monoclonal anti-b-tubulin (1/5000,Sigma),
and revealed with appropriate anti-rabbit or anti-mouse peroxi-
dase-conjugated secondary antibodies (1/5000, Jackson Immu-
noResearch Laboratories) and the enhanced chemiluminescent
(ECL) detection system (Pierce).
Rho Activation Assay
Rho activation was analyzed using Rho assay kit (Upstate
Biotechnology). After DA (100 mM) and quinpirole (10 mM)
treatments for 15 min, cells were lysed in 50 mM Tris-HCl,
pH 7,5, 150 mM NaCl, 2 mM EDTA, 1 mM sodium orthova-
nadate, 50 mM MgCl2, 0,1% SDS, 1% Nonidet P-40, 1% sodium
deoxycholate and complete protease inhibitor cocktail (Sigma) for
15 min at 4uC. The Rho active form, Rho-GTP, was specifically
immunoprecipitated from these lysates incubating with Rho Assay
Reagent (Rhotekin fused to the Rho Binding Domain on agarose
beads) for 45 min at 4uC on a rotator. After a short spin, the pellet
beads were washed three times with lysis buffer and resuspended
in 25 ml of 2X Laemmli buffer. Rho-GTP activated bound to
rhotekin-agarose beads was subjected to 15% SDS-PAGE,
followed by Western blotting with mouse monoclonal anti-Rho
(-A,-B,-C) antibody (1/250, Upstate).
Statistical Analysis
All data were statistically analyzed using GraphPad Prism
(GrahPad Software Inc., San Diego,CA). Two-way ANOVA
followed by post hoc Bonferroni’s test was carried out and for all
statistical analyses the difference between comparisons was
considered to be significant when P,0.05.
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